Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo Pharmaceuticals, Inc. of $300 million aggregate principal amount of its 3.25% convertible senior notes due 2021, including $40 million aggregate principal amount of notes sold pursuant to the initial purchaser’s full exercise of its option to purchase additional notes, solely to cover over-allotments. Sucampo’s Class A common stock is listed on the NASDAQ Global Market under the symbol “SCMP.”

Sucampo is a global biopharmaceutical company focused on developing, identifying, acquiring and bringing to market innovative medicines that meet unmet medical needs. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.

The Davis Polk capital markets team included partner Sophia Hudson and associate Christopher M. Bezeg. The equity derivatives team included partner Mark M. Mendez and associates Barry J. Gewolb and Caitlin L. Wood. The tax team included partner Po Sit and associate Rachel Lerner. Counsel David R. Bauer and associate Tilak Koilvaram provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.